

**PTAFR Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13382b****Specification**

---

**PTAFR Antibody (C-term) Blocking peptide - Product Information**Primary Accession [P25105](#)**PTAFR Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 5724**Other Names**

Platelet-activating factor receptor, PAF-R, PAFr, PTAFR, PAFR

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13382b was selected from the C-term region of PTAFR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PTAFR Antibody (C-term) Blocking peptide - Protein Information****Name** PTAFR**Synonyms** PAFR**Function**

Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol-calcium second messenger system.

**Cellular Location**

Cell membrane; Multi-pass membrane protein

**Tissue Location**

Expressed in the placenta, lung, left and right heart ventricles, heart atrium, leukocytes and differentiated HL-60 granulocytes.

**PTAFR Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**PTAFR Antibody (C-term) Blocking peptide - Images****PTAFR Antibody (C-term) Blocking peptide - Background**

PTAFR shows structural characteristics of the rhodopsin(MIM 180380) gene family and binds platelet-activating factor(PAF). PAF is a phospholipid(1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) that has been implicated as a mediator in diverse pathologic processes, such as allergy, asthma, septic shock, arterial thrombosis, and inflammatory processes.

**PTAFR Antibody (C-term) Blocking peptide - References**

Balestrieri, M.L., et al. Biochim. Biophys. Acta 1801(10):1123-1132(2010) Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Kajiwar, N., et al. J. Allergy Clin. Immunol. 125(5):1137-1145(2010) Davila, S., et al. Genes Immun. 11(3):232-238(2010) Keely, S., et al. Mol. Biol. Cell 21(4):538-546(2010)